ATE480236T1 - Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans - Google Patents
Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliteransInfo
- Publication number
- ATE480236T1 ATE480236T1 AT02720584T AT02720584T ATE480236T1 AT E480236 T1 ATE480236 T1 AT E480236T1 AT 02720584 T AT02720584 T AT 02720584T AT 02720584 T AT02720584 T AT 02720584T AT E480236 T1 ATE480236 T1 AT E480236T1
- Authority
- AT
- Austria
- Prior art keywords
- mrna expression
- pioglitazone
- treatment
- promoting agent
- expression promoter
- Prior art date
Links
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 title 2
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 title 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 title 1
- 229960005095 pioglitazone Drugs 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 108020004999 messenger RNA Proteins 0.000 abstract 4
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 101150092476 ABCA1 gene Proteins 0.000 abstract 1
- 108091028119 ACAT1 mRNA Proteins 0.000 abstract 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 abstract 1
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 abstract 1
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 abstract 1
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- -1 cholesteryl ester Chemical class 0.000 abstract 1
- 102000004311 liver X receptors Human genes 0.000 abstract 1
- 108090000865 liver X receptors Proteins 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001128222 | 2001-04-25 | ||
| PCT/JP2002/004072 WO2002087580A1 (en) | 2001-04-25 | 2002-04-24 | Abc expression promoters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE480236T1 true ATE480236T1 (de) | 2010-09-15 |
Family
ID=18976958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02720584T ATE480236T1 (de) | 2001-04-25 | 2002-04-24 | Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040077689A1 (de) |
| EP (1) | EP1382336B1 (de) |
| AT (1) | ATE480236T1 (de) |
| CA (1) | CA2445322C (de) |
| DE (1) | DE60237594D1 (de) |
| WO (1) | WO2002087580A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| NZ531346A (en) * | 2001-08-28 | 2005-10-28 | Sankyo Co | Medicinal compositions containing angiotensin II receptor antagonist |
| TW200606157A (en) * | 2004-07-02 | 2006-02-16 | Sankyo Co | Suppressant of production of tissue factor |
| KR101021828B1 (ko) | 2004-10-27 | 2011-03-17 | 다이이찌 산쿄 가부시키가이샤 | 2 이상의 치환기를 갖는 벤젠 화합물 |
| US8097610B2 (en) * | 2005-08-26 | 2012-01-17 | Shionogi & Co., Ltd. | Derivative having PPAR agonistic activity |
| CL2008003699A1 (es) * | 2007-12-13 | 2009-10-09 | Takeda Pharmaceuticals Co | Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas. |
| US20160199497A1 (en) * | 2014-09-10 | 2016-07-14 | Purdue Research Foundation | Cholesterol Ester-Depleting Nanomedicine for Non-toxic Cancer Chemotherapy |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US5057494A (en) * | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
| US5356913A (en) * | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
| US5798375A (en) * | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| KR20000005224A (ko) * | 1996-04-04 | 2000-01-25 | 가와무라 요시부미 | 페닐알킬카르복실산 유도체_ |
| AU4050797A (en) * | 1996-08-02 | 1998-02-25 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
| JPH1072371A (ja) * | 1996-08-28 | 1998-03-17 | Sankyo Co Ltd | 回腸型胆汁酸トランスポーター阻害剤 |
| ES2320181T3 (es) * | 1997-07-24 | 2009-05-19 | Astellas Pharma Inc. | Composiciones farmaceuticas que tienen un efecto reductor del colesterol. |
| US5893865A (en) * | 1997-09-23 | 1999-04-13 | Baxter Research Medical, Inc. | Apparatus and method for improved aortic incision |
| AU740733B2 (en) * | 1997-12-19 | 2001-11-15 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| MY123337A (en) * | 1998-05-11 | 2006-05-31 | Takeda Chemical Industries Ltd | Oxyiminoalkanoic acid derivatives. |
| WO1999059586A1 (en) * | 1998-05-19 | 1999-11-25 | Regents Of The University Of California | Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis |
| US5968960A (en) * | 1999-01-14 | 1999-10-19 | The Regents Of The University Of California | Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism |
| TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| US6436993B1 (en) * | 1999-07-13 | 2002-08-20 | The Salk Institute For Biological Studies | Use of RAR antagonists as modulators of hormone mediated processes |
| ATE260912T1 (de) * | 1999-09-08 | 2004-03-15 | Glaxo Group Ltd | Oxazol ppar antagonisten |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| EP1304121A4 (de) * | 1999-11-10 | 2004-06-23 | Takeda Chemical Industries Ltd | Inhibitoren der koerpergewichtszunahme |
| EP1229026A4 (de) * | 1999-11-10 | 2003-09-24 | Takeda Chemical Industries Ltd | Alkoxyiminoalkansäure-derivate |
| ES2225252T3 (es) * | 1999-11-10 | 2005-03-16 | Takeda Chemical Industries, Ltd. | Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica. |
| IL151517A0 (en) * | 2000-03-09 | 2003-04-10 | Aventis Pharma Gmbh | Therapeutic uses of ppar mediators |
-
2002
- 2002-04-24 AT AT02720584T patent/ATE480236T1/de not_active IP Right Cessation
- 2002-04-24 US US10/468,433 patent/US20040077689A1/en not_active Abandoned
- 2002-04-24 EP EP02720584A patent/EP1382336B1/de not_active Expired - Lifetime
- 2002-04-24 CA CA2445322A patent/CA2445322C/en not_active Expired - Fee Related
- 2002-04-24 WO PCT/JP2002/004072 patent/WO2002087580A1/ja not_active Ceased
- 2002-04-24 DE DE60237594T patent/DE60237594D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2445322A1 (en) | 2002-11-07 |
| EP1382336A4 (de) | 2007-08-08 |
| WO2002087580A1 (en) | 2002-11-07 |
| DE60237594D1 (de) | 2010-10-21 |
| EP1382336A1 (de) | 2004-01-21 |
| CA2445322C (en) | 2011-06-14 |
| EP1382336B1 (de) | 2010-09-08 |
| US20040077689A1 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE327753T1 (de) | Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes | |
| DE60229041D1 (de) | Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen | |
| ATE524479T1 (de) | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren | |
| DE60036169D1 (de) | Methoden zur Behandlung der Hautpigmentierung | |
| DE60328517D1 (de) | Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung | |
| ATE374641T1 (de) | Kombinationen vom ppar-aktivator fenofibrat mit dem hemmer der sterol-absorption ezetimibe zur behandlung von kardiovaskulären indikationen | |
| CY1108563T1 (el) | Μεθοδοι και υλικα για τη θεραπεια της ανεπαρκειας (ελλειψης) τεστοστερονης στους ανδρες | |
| DE60335997D1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
| ATE346614T1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
| WO2004043954A3 (en) | Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same | |
| DE60137307D1 (de) | Substituierte sapogenine und ihre verwendung | |
| ATE302017T1 (de) | Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden | |
| DE60012774D1 (de) | Zusammensetzungen mit hydroxyeicosatetraensäure derivate und verfahren zur verwendung zur behandlung des trockenen auges | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| ATE469886T1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen | |
| DE60237594D1 (de) | Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans | |
| ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| ATE337005T1 (de) | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| SE0301883D0 (sv) | New use II | |
| ATE287713T1 (de) | Verwendung von riluzol zur behandlung multipler sklerose | |
| DE50212649D1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
| ATE315387T1 (de) | Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz | |
| ATE273013T1 (de) | Verwendung von simethicone zur behandlung der ulzerativen kolitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |